Sign inJoin waitlistJoin the waitlist

Noah Federman

Program Director · UCLA David Geffen School of Medicine/UCLA Medical Center

Credentials: · · ·

History

UCLA David Geffen School of Medicine/UCLA Medical Center
Present
UCLA-CTSI Clinical and Translational Research Center · UCLA David Geffen School of Medicine/UCLA Medical Center
Present
UCLA-CTSI Data Safety Monitoring Board Department · UCLA David Geffen School of Medicine/UCLA Medical Center
Present

Pediatric Hematology Oncology
UCLA David Geffen School of Medicine/UCLA Medical Center
2005–2008
Pediatrics
UCLA David Geffen School of Medicine/UCLA Medical Center
2002–2003
Icahn School of Medicine at Mount Sinai
1998–2002

Research

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
New England Journal of Medicine · 2018 · 2,193 citations
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
The Lancet Oncology · 2020 · 835 citations
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
The Lancet Oncology · 2018 · 458 citations

Arun Singh
21 papers
SN
Scott Nelson
21 papers
Nicholas Bernthal
20 papers · 2 as a resident
Sarah Dry
18 papers
Bartosz Chmielowski
12 papers
Joseph Crompton
11 papers · 3 as a fellow
SC
Sant Chawla
10 papers
Mark Eckhardt
9 papers · 5 as a resident
Jane Yanagawa
8 papers
WT
William Tap
8 papers · 1 as a fellow
Anusha Kalbasi
7 papers · 1 as a resident
Christopher Denny
7 papers

Clinical trials

Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma
Principal investigator · Active not recruiting · Phase 1
Jonsson Comprehensive Cancer Center
2020–2027
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2026–2031
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2029
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Site PI · Recruiting · Phase 3
Children's Oncology Group
2022–2030